Contact Information
AddressKiang Wu Hospital
Estrada do Repouso
Macau
yabing-cao
Phone(853)2837 1333
Emailsumscaoyabing@hotmal.com
Contact in UMOffice: E12-4031
Tel: (853)8822 4930
Email: yabingcao@um.edu.mo
Education
Ph.D. candidate of Medical OncologySun Yat-sen University, Guangzhou, China
Master of Medical OncologySun Yat-sen University, Guangzhou, China
Bachelor of MedicineHenan Medical University, Zhengzhou, China
Positions
2016 to presentAdjunct Associate Professor, Faculty of Health Sciences, University of Macau
2010 to presentAttending Physician, Medical Oncologist,
Department of Oncology, Kiang Wu Hospital
Representative Publications
  • Huang, H., Li, X., Zhu, J., Ye, S., Zhang, H., Wang, W., Wu, X., Peng, J., Xu, B., Lin, Y., Cao, Y., Li, H., Lin, S., Liu, Q. & Lin, T. (2014). Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial. JAMA 312, 2521-30. (IF: 30.3)
  • Cao, Y., Xiao, G., Qiu, X., Ye, S. & Lin, T. (2014). Efficacy and safety of crizotinib among Chinese EML4-ALK-positive, advanced-stage non-small cell lung cancer patients. PLoS One 9, e114008. (IF: 3.5)
  • Xiao, G., Cao, Y., Qiu, X., Wang, W. & Wang, Y. (2013). Influence of gender and age on the survival of patients with nasopharyngeal carcinoma. BMC Cancer 13, 226. (IF: 3.3)
  • Huang, Y., Ye, S., Cao, Y., Li, Z., Huang, J., Huang, H., Cai, M., Luo, R. & Lin, T. (2012). Outcome of R-CHOP or CHOP regimen for germinal center and nongerminal center subtypes of diffuse large B-cell lymphoma of Chinese patients. Scientific World Journal 2012, 897178.2. (IF:3.5)
  • Cao, Y., Lan, Y., Qian, J., Zheng, Y., Hong, S., Li, H., Wang, M., Kwak, L. W., Lin, D., Yang, J. & Yi, Q. (2011). Targeting cell surface beta2 -microglobulin by pentameric IgM antibodies. Br J Haematol 154,
    111-21. (IF: 4.9)
  • Zhai, L., Guo, C., Cao, Y., Xiao, J., Fu, X., Huang, J., Huang, H., Guan, Z. & Lin, T. (2010). Long-term results of pirarubicin versus doxorubicin in combination chemotherapy for aggressive non-Hodgkin’s lymphoma: single center, 15-year experience. Int J Hematol 91, 78-86. (IF: 1.6)
  • Yang, J., Cao, Y., Hong, S., Li, H., Qian, J., Kwak, L. W. & Yi, Q. (2009). Human-like mouse models for testing the efficacy and safety of anti-beta2-microglobulin monoclonal antibodies to treat myeloma. Clin Cancer Res 15, 951-9. (IF: 8.1)
Honours / Awards
  • 2014 Science and Technology Award of Macau (3rd class)
  • 2013 National Future Star of Oncology Research, Chinese Medical Association (Top 10)